<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} ImmunityImmunityImmunity1074-76131097-4180Elsevier Inc. pmcid: 7237932S1074-7613(20)30212-0 doi: 10.1016/j.immuni.2020.05.004 : Article" exact="Respiratory" post="Virus Infections: Understanding COVID-19 SubbaraoKantakanta.subbarao@influenzacentre.org1âˆ—MahantySiddhartha2[1], [2], âˆ—Corresponding author kanta.subbarao@influenzacentre.org"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Respiratory" post="viruses affect us throughout our lives, from infancy to"/>
 <result pre="belong to several virus families, and although many features of" exact="infection" post="with these diverse viruses are shared, some have unique"/>
 <result pre="Here we explain what happens when we are infected by" exact="respiratory" post="viruses, including SARS-CoV-2, which causes COVID-19. Respiratory viruses affect"/>
 <result pre="are infected by respiratory viruses, including SARS-CoV-2, which causes COVID-19." exact="Respiratory" post="viruses affect us throughout our lives, from infancy to"/>
 <result pre="belong to several virus families, and although several features of" exact="infection" post="with these diverse viruses are shared, some have unique"/>
 <result pre="Here we explain what happens when we are infected by" exact="respiratory" post="viruses, including SARS-CoV-2, which causes COVID-19. Main Text Basic"/>
 <result pre="including SARS-CoV-2, which causes COVID-19. Main Text Basic Concepts about" exact="Respiratory" post="Viruses Viral respiratory infections result when a virus infects"/>
 <result pre="which causes COVID-19. Main Text Basic Concepts about Respiratory Viruses" exact="Viral" post="respiratory infections result when a virus infects the cells"/>
 <result pre="causes COVID-19. Main Text Basic Concepts about Respiratory Viruses Viral" exact="respiratory" post="infections result when a virus infects the cells of"/>
 <result pre="COVID-19. Main Text Basic Concepts about Respiratory Viruses Viral respiratory" exact="infections" post="result when a virus infects the cells of the"/>
 <result pre="infections result when a virus infects the cells of the" exact="respiratory" post="mucosa; this can occur when virus particles are inhaled"/>
 <result pre="large droplets that fall out of the air within a" exact="short" post="distance. If the virus falls on a surface and"/>
 <result pre="long periods of time and can be inhaled into the" exact="lower" post="respiratory tract. The relative contribution of different particle sizes"/>
 <result pre="periods of time and can be inhaled into the lower" exact="respiratory" post="tract. The relative contribution of different particle sizes and"/>
 <result pre="airborne transmission as a means of spread differs among the" exact="respiratory" post="viruses. Influenza viruses are spread by contact as well"/>
 <result pre="by airborne transmission, but the mode of transmission of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is still being discussed."/>
 <result pre="airborne transmission, but the mode of transmission of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is still being discussed. Some"/>
 <result pre="transmission, but the mode of transmission of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is still being discussed. Some viruses"/>
 <result pre="discussed. Some viruses are more fragile than others; for example," exact="respiratory" post="syncytial virus (RSV), the most important respiratory virus in"/>
 <result pre="others; for example, respiratory syncytial virus (RSV), the most important" exact="respiratory" post="virus in early childhood, does not survive for long"/>
 <result pre="for long on inanimate surfaces, whereas coronaviruses are much more" exact="stable" post="in the environment (van Doremalen etÂ al., 2020). Infection"/>
 <result pre="more stable in the environment (van Doremalen etÂ al., 2020)." exact="Infection" post="control and prevention strategies are designed based on these"/>
 <result pre="special air handling. What Happens When the Virus Reaches the" exact="Respiratory" post="Mucosa? The respiratory epithelium is composed of a variety"/>
 <result pre="What Happens When the Virus Reaches the Respiratory Mucosa? The" exact="respiratory" post="epithelium is composed of a variety of cells that"/>
 <result pre="of a variety of cells that include ciliated and non-ciliated" exact="epithelial" post="cells; goblet cells, which produce mucus that forms the"/>
 <result pre="an incoming virus; and club cells, which produce proteases. Different" exact="respiratory" post="viruses preferentially bind and infect ciliated or non-ciliated epithelial"/>
 <result pre="Different respiratory viruses preferentially bind and infect ciliated or non-ciliated" exact="epithelial" post="cells of the airways: pneumocytes lining the alveoli in"/>
 <result pre="lungs and alveolar macrophages (Matrosovich etÂ al., 2004). For example," exact="avian influenza" post="A viruses infect ciliated epithelial cells, whereas human influenza"/>
 <result pre="al., 2004). For example, avian influenza A viruses infect ciliated" exact="epithelial" post="cells, whereas human influenza viruses infect non-ciliated epithelial cells."/>
 <result pre="infect ciliated epithelial cells, whereas human influenza viruses infect non-ciliated" exact="epithelial" post="cells. The presence of specific host cell molecules that"/>
 <result pre="presence of specific host cell molecules that are receptors for" exact="viral" post="attachment and entry are the main determinants of which"/>
 <result pre="for human coronavirus NL63. The receptor for the Middle East" exact="respiratory" post="syndrome (MERS) coronavirus is human dipeptidyl peptidase 4 (DPP4),"/>
 <result pre="human coronavirus NL63. The receptor for the Middle East respiratory" exact="syndrome" post="(MERS) coronavirus is human dipeptidyl peptidase 4 (DPP4), and"/>
 <result pre="human influenza viruses bind sialic acids with Î±2,6-linked oligosaccharides, whereas" exact="avian influenza" post="viruses bind sialic acids with Î±2,3-linked oligosaccharides (reviewed in"/>
 <result pre="Paules and Subbarao, 2017). The presence of cells in the" exact="respiratory" post="tract expressing the relevant viral receptor is critical for"/>
 <result pre="presence of cells in the respiratory tract expressing the relevant" exact="viral" post="receptor is critical for initiation of viral infection, and"/>
 <result pre="expressing the relevant viral receptor is critical for initiation of" exact="viral infection," post="and the clinical presentation depends on where these cells"/>
 <result pre="presentation depends on where these cells are situated in the" exact="respiratory" post="tract. For example, if cells bearing the viral receptor"/>
 <result pre="in the respiratory tract. For example, if cells bearing the" exact="viral" post="receptor are only present in the upper respiratory tract,"/>
 <result pre="cells bearing the viral receptor are only present in the" exact="upper" post="respiratory tract, then infection is likely to be limited"/>
 <result pre="bearing the viral receptor are only present in the upper" exact="respiratory" post="tract, then infection is likely to be limited to"/>
 <result pre="receptor are only present in the upper respiratory tract, then" exact="infection" post="is likely to be limited to rhinitis (characterized by"/>
 <result pre="the upper respiratory tract, then infection is likely to be" exact="limited" post="to rhinitis (characterized by a runny nose and stuffiness)"/>
 <result pre="respiratory tract, then infection is likely to be limited to" exact="rhinitis" post="(characterized by a runny nose and stuffiness) or pharyngitis"/>
 <result pre="is likely to be limited to rhinitis (characterized by a" exact="runny nose" post="and stuffiness) or pharyngitis (sore throat) (FigureÂ 1 )."/>
 <result pre="to rhinitis (characterized by a runny nose and stuffiness) or" exact="pharyngitis" post="(sore throat) (FigureÂ 1 ). In contrast, if the"/>
 <result pre="pharyngitis (sore throat) (FigureÂ 1 ). In contrast, if the" exact="viral" post="receptor is present on cells in the lower respiratory"/>
 <result pre="if the viral receptor is present on cells in the" exact="lower" post="respiratory tract (e.g., epithelial cells expressing Î±2,3-linked sialic acids"/>
 <result pre="the viral receptor is present on cells in the lower" exact="respiratory" post="tract (e.g., epithelial cells expressing Î±2,3-linked sialic acids beyond"/>
 <result pre="is present on cells in the lower respiratory tract (e.g.," exact="epithelial" post="cells expressing Î±2,3-linked sialic acids beyond the respiratory bronchioles"/>
 <result pre="tract (e.g., epithelial cells expressing Î±2,3-linked sialic acids beyond the" exact="respiratory" post="bronchioles in the lungs), then the infecting virus (e.g.,"/>
 <result pre="respiratory bronchioles in the lungs), then the infecting virus (e.g.," exact="avian influenza" post="A(H5N1) virus) causes lower respiratory tract infection. FigureÂ 1"/>
 <result pre="then the infecting virus (e.g., avian influenza A(H5N1) virus) causes" exact="lower" post="respiratory tract infection. FigureÂ 1 Schematic Illustration of the"/>
 <result pre="the infecting virus (e.g., avian influenza A(H5N1) virus) causes lower" exact="respiratory" post="tract infection. FigureÂ 1 Schematic Illustration of the Human"/>
 <result pre="respiratory tract infection. FigureÂ 1 Schematic Illustration of the Human" exact="Respiratory" post="Tract, Indicating the Clinical Presentations Associated with Different Respiratory"/>
 <result pre="Human Respiratory Tract, Indicating the Clinical Presentations Associated with Different" exact="Respiratory" post="Viruses that Infect Particular Parts of the Upper and"/>
 <result pre="Viruses that Infect Particular Parts of the Upper and Lower" exact="Respiratory" post="Tract After attachment to the receptor, the virus gains"/>
 <result pre="that Infect Particular Parts of the Upper and Lower Respiratory" exact="Tract" post="After attachment to the receptor, the virus gains entry"/>
 <result pre="receptor, the virus gains entry into the cell, and the" exact="viral" post="genome is uncoated, releasing the viral genetic material, which"/>
 <result pre="the cell, and the viral genome is uncoated, releasing the" exact="viral" post="genetic material, which is RNA in paramyxoviruses, orthomyxoviruses, and"/>
 <result pre="RNA in paramyxoviruses, orthomyxoviruses, and coronaviruses and DNA in adenoviruses." exact="Viral" post="transcription to produce viral proteins and viral replication to"/>
 <result pre="and coronaviruses and DNA in adenoviruses. Viral transcription to produce" exact="viral" post="proteins and viral replication to copy the viral genome"/>
 <result pre="DNA in adenoviruses. Viral transcription to produce viral proteins and" exact="viral" post="replication to copy the viral genome are complex events"/>
 <result pre="to produce viral proteins and viral replication to copy the" exact="viral" post="genome are complex events unique to each viral family"/>
 <result pre="copy the viral genome are complex events unique to each" exact="viral" post="family and occur in specific cellular compartments, although all"/>
 <result pre="ends of host cell messenger RNA (mRNA) as primers for" exact="viral" post="mRNAs. The replication cycle of coronaviruses occurs entirely in"/>
 <result pre="Progeny virions are released from the infected cell into the" exact="respiratory" post="tract, where they are shed by coughing and sneezing."/>
 <result pre="coughing and sneezing. When host cells are infected by viruses," exact="type I" post="interferons (IFNs) and pro-inflammatory cytokines are expressed, cellular translation"/>
 <result pre="is suppressed, and an antiviral state is induced. However, many" exact="respiratory" post="viruses are able to block IFN activation and/or signaling"/>
 <result pre="and also induces an antiviral state in neighboring cells, promoting" exact="viral" post="replication in infected tissues that may contribute to the"/>
 <result pre="contribute to the observed pathology. What Are the Consequences of" exact="Infection" post="in the Host? When a person is infected with"/>
 <result pre="in the Host? When a person is infected with a" exact="respiratory" post="virus, there is an incubation period before onset of"/>
 <result pre="SARS-CoV-2, it is 4.5â€&quot;5.8Â days (Lauer etÂ al., 2020). Productive" exact="viral infection" post="of respiratory epithelial cells results in clinical symptoms and"/>
 <result pre="it is 4.5â€&quot;5.8Â days (Lauer etÂ al., 2020). Productive viral" exact="infection" post="of respiratory epithelial cells results in clinical symptoms and"/>
 <result pre="4.5â€&quot;5.8Â days (Lauer etÂ al., 2020). Productive viral infection of" exact="respiratory" post="epithelial cells results in clinical symptoms and signs that"/>
 <result pre="days (Lauer etÂ al., 2020). Productive viral infection of respiratory" exact="epithelial" post="cells results in clinical symptoms and signs that depend"/>
 <result pre="symptoms and signs that depend on which part of the" exact="respiratory" post="tract is infected (FigureÂ 1). Infection of the nasal,"/>
 <result pre="which part of the respiratory tract is infected (FigureÂ 1)." exact="Infection" post="of the nasal, nasopharyngeal, and oropharyngeal mucosa causes a"/>
 <result pre="infected (FigureÂ 1). Infection of the nasal, nasopharyngeal, and oropharyngeal" exact="mucosa" post="causes a runny nose, coughing, sneezing, and sore throat,"/>
 <result pre="Infection of the nasal, nasopharyngeal, and oropharyngeal mucosa causes a" exact="runny nose," post="coughing, sneezing, and sore throat, whereas tracheobronchitis or croup"/>
 <result pre="runny nose, coughing, sneezing, and sore throat, whereas tracheobronchitis or" exact="croup" post="presents with a characteristic barking seal-like cough. Bronchitis refers"/>
 <result pre="bronchiolitis, involving the smaller distal airways, is characteristic of RSV" exact="infection" post="in young infants and presents with wheezing. Pneumonia occurs"/>
 <result pre="of RSV infection in young infants and presents with wheezing." exact="Pneumonia" post="occurs when infection and inflammation involve the alveoli and"/>
 <result pre="in young infants and presents with wheezing. Pneumonia occurs when" exact="infection" post="and inflammation involve the alveoli and lung parenchyma and"/>
 <result pre="cough and shortness of breath. Rhinovirus, adenovirus, and human coronavirus" exact="infections" post="are usually limited to the upper respiratory tract. Parainfluenza"/>
 <result pre="of breath. Rhinovirus, adenovirus, and human coronavirus infections are usually" exact="limited" post="to the upper respiratory tract. Parainfluenza viruses cause croup,"/>
 <result pre="adenovirus, and human coronavirus infections are usually limited to the" exact="upper" post="respiratory tract. Parainfluenza viruses cause croup, RSV causes bronchiolitis"/>
 <result pre="and human coronavirus infections are usually limited to the upper" exact="respiratory" post="tract. Parainfluenza viruses cause croup, RSV causes bronchiolitis and"/>
 <result pre="the upper respiratory tract. Parainfluenza viruses cause croup, RSV causes" exact="bronchiolitis" post="and influenza, and SARS, MERS, and SARS-CoV-2 can cause"/>
 <result pre="bronchiolitis and influenza, and SARS, MERS, and SARS-CoV-2 can cause" exact="pneumonia" post="(FigureÂ 1). Sometimes respiratory viral infections are complicated by"/>
 <result pre="SARS, MERS, and SARS-CoV-2 can cause pneumonia (FigureÂ 1). Sometimes" exact="respiratory" post="viral infections are complicated by secondary bacterial infection, particularly"/>
 <result pre="MERS, and SARS-CoV-2 can cause pneumonia (FigureÂ 1). Sometimes respiratory" exact="viral" post="infections are complicated by secondary bacterial infection, particularly in"/>
 <result pre="and SARS-CoV-2 can cause pneumonia (FigureÂ 1). Sometimes respiratory viral" exact="infections" post="are complicated by secondary bacterial infection, particularly in the"/>
 <result pre="pneumonia (FigureÂ 1). Sometimes respiratory viral infections are complicated by" exact="secondary" post="bacterial infection, particularly in the middle ear (otitis media)"/>
 <result pre="(FigureÂ 1). Sometimes respiratory viral infections are complicated by secondary" exact="bacterial infection," post="particularly in the middle ear (otitis media) or lungs"/>
 <result pre="media) or lungs (pneumonia). The best example of this is" exact="secondary" post="bacterial infection caused by Streptococcus pneumoniae or Staphylococcus aureus"/>
 <result pre="or lungs (pneumonia). The best example of this is secondary" exact="bacterial infection" post="caused by Streptococcus pneumoniae or Staphylococcus aureus following influenza"/>
 <result pre="lungs (pneumonia). The best example of this is secondary bacterial" exact="infection" post="caused by Streptococcus pneumoniae or Staphylococcus aureus following influenza"/>
 <result pre="infection caused by Streptococcus pneumoniae or Staphylococcus aureus following influenza" exact="virus infection." post="During the 1918 and 2009 influenza pandemics, a large"/>
 <result pre="influenza pandemics, a large proportion of the deaths resulted from" exact="secondary" post="bacterial pneumonia. The Immune Response to Respiratory Viruses The"/>
 <result pre="pandemics, a large proportion of the deaths resulted from secondary" exact="bacterial pneumonia." post="The Immune Response to Respiratory Viruses The immune system"/>
 <result pre="deaths resulted from secondary bacterial pneumonia. The Immune Response to" exact="Respiratory" post="Viruses The immune system responds to viral infection with"/>
 <result pre="Immune Response to Respiratory Viruses The immune system responds to" exact="viral infection" post="with cellular and humoral (antibodies, complement, and antimicrobial peptides)"/>
 <result pre="Response to Respiratory Viruses The immune system responds to viral" exact="infection" post="with cellular and humoral (antibodies, complement, and antimicrobial peptides)"/>
 <result pre="by tissue injury, or pathogen-associated molecular patterns (PAMPs), such as" exact="viral" post="RNA or oxidized phospholipids from invading pathogens. DAMPs and"/>
 <result pre="phospholipids from invading pathogens. DAMPs and PAMPs released during initial" exact="infection" post="and lysis of pneumocytes (surface epithelial cells of the"/>
 <result pre="PAMPs released during initial infection and lysis of pneumocytes (surface" exact="epithelial" post="cells of the alveoli) activate multiple innate immune pathways"/>
 <result pre="and differentiation of naive CD8+ and CD4+ TÂ cells. Effective" exact="viral" post="clearance requires CD8+ effector TÂ cell-mediated killing of virally"/>
 <result pre="G (IgG) is the dominant antibody involved in protection from" exact="respiratory" post="viruses in the lower respiratory tract, whereas mucosal IgA"/>
 <result pre="dominant antibody involved in protection from respiratory viruses in the" exact="lower" post="respiratory tract, whereas mucosal IgA plays an important role"/>
 <result pre="antibody involved in protection from respiratory viruses in the lower" exact="respiratory" post="tract, whereas mucosal IgA plays an important role in"/>
 <result pre="mucosal IgA plays an important role in immunity in the" exact="upper" post="respiratory tract. Although cellular and humoral responses contribute to"/>
 <result pre="IgA plays an important role in immunity in the upper" exact="respiratory" post="tract. Although cellular and humoral responses contribute to clearance"/>
 <result pre="tract. Although cellular and humoral responses contribute to clearance of" exact="primary" post="infection, neutralizing antibodies play a critical role in protection"/>
 <result pre="neutralizing antibodies play a critical role in protection against re-infection." exact="Immunological" post="memory is maintained by T and B cell subsets"/>
 <result pre="B cell â€œexhaustion.â€� This phenotype has been reported in many" exact="chronic" post="viral infections and is frequently associated with lymphopenia. In"/>
 <result pre="cell â€œexhaustion.â€� This phenotype has been reported in many chronic" exact="viral" post="infections and is frequently associated with lymphopenia. In these"/>
 <result pre="â€œexhaustion.â€� This phenotype has been reported in many chronic viral" exact="infections" post="and is frequently associated with lymphopenia. In these settings,"/>
 <result pre="PD-1, Tim-3, MKI67, and TYMS (Blank etÂ al., 2019). Notably," exact="lymphopenia" post="and TÂ cell exhaustion have been observed in recent"/>
 <result pre="lymphopenia and TÂ cell exhaustion have been observed in recent" exact="viral" post="epidemics caused by SARS and pandemic H1N1 influenza. What"/>
 <result pre="H1N1 influenza. What Happens in COVID-19? After an incubation period," exact="infection" post="progresses from the pre-symptomatic stage (1â€&quot;3Â days) through symptomatic"/>
 <result pre="period, infection progresses from the pre-symptomatic stage (1â€&quot;3Â days) through" exact="symptomatic" post="infection (2â€&quot;4Â weeks) to a prolonged post-symptomatic or recovery"/>
 <result pre="infection progresses from the pre-symptomatic stage (1â€&quot;3Â days) through symptomatic" exact="infection" post="(2â€&quot;4Â weeks) to a prolonged post-symptomatic or recovery stage"/>
 <result pre="recovery stage (2â€&quot;8Â weeks) (FigureÂ 2 ). The spectrum of" exact="disease" post="with SARS-CoV-2 ranges from asymptomatic infection to severe, often"/>
 <result pre="). The spectrum of disease with SARS-CoV-2 ranges from asymptomatic" exact="infection" post="to severe, often fatal disease. Patients with mild disease"/>
 <result pre="asymptomatic infection to severe, often fatal disease. Patients with mild" exact="disease" post="(80%) have fever, cough, sore throat, loss of smell,"/>
 <result pre="body aches. Moderate illness is characterized by involvement of the" exact="lower" post="respiratory tract. In influenza, the amount of infecting virus"/>
 <result pre="aches. Moderate illness is characterized by involvement of the lower" exact="respiratory" post="tract. In influenza, the amount of infecting virus (inoculum)"/>
 <result pre="this is true for SARS-CoV-2; notably, asymptomatic patients with coronavirus" exact="disease" post="2019 (COVID-19; 10%â€&quot;50% of infections) can excrete large quantities"/>
 <result pre="can be divided into three phases: pre-symptomatic, symptomatic, and recovery." exact="Viral" post="replication occurs during the late pre-symptomatic and early symptomatic"/>
 <result pre="recovery. Viral replication occurs during the late pre-symptomatic and early" exact="symptomatic" post="phases. Innate immune responses follow, including activation of macrophages,"/>
 <result pre="and TÂ cells are detected within the first week of" exact="infection" post="in mild to moderate COVID-19 cases (Thevarajan etÂ al.,"/>
 <result pre="bottom panel illustrates optimal timing of potential interventions based on" exact="viral" post="and immune kinetics. Immunomodulators are genetically engineered or organism-derived"/>
 <result pre="organism-derived proteins that target specific parts of the immune system." exact="Severe" post="infection and complications occur more frequently in males and"/>
 <result pre="proteins that target specific parts of the immune system. Severe" exact="infection" post="and complications occur more frequently in males and those"/>
 <result pre="those with underlying medical conditions (called co-morbidities), including hypertension, diabetes," exact="cardiovascular disease," post="and immunocompromised states. Findings associated with poor outcomes include"/>
 <result pre="lymphopenia, a prolonged prothrombin time (indicating coagulopathy), and elevated levels" exact="of liver" post="enzymes, lactate dehydrogenase, D-dimer, interleukin-6, C-reactive protein, and procalcitonin"/>
 <result pre="procalcitonin (Gandhi etÂ al., 2020). The pathogenesis of severe SARS-CoV-2" exact="infection" post="is complex, and we are still learning about it"/>
 <result pre="learning about it at the time of this writing. The" exact="viral" post="spike glycoprotein binds to the cell surface receptor ACE2"/>
 <result pre="the nose and lungs are endowed with ACE2, which facilitates" exact="infection" post="of the respiratory tract. However, ACE2 is also expressed"/>
 <result pre="lungs are endowed with ACE2, which facilitates infection of the" exact="respiratory" post="tract. However, ACE2 is also expressed on cells in"/>
 <result pre="endothelium, heart, gut, and kidneys, making these organs susceptible to" exact="infection" post="by the virus. A prominent feature of severe SARS-CoV-2"/>
 <result pre="infection by the virus. A prominent feature of severe SARS-CoV-2" exact="infections" post="is the cytokine release syndrome. SARS-CoV-2 infection of respiratory"/>
 <result pre="of severe SARS-CoV-2 infections is the cytokine release syndrome. SARS-CoV-2" exact="infection" post="of respiratory epithelial cells activates monocytes, macrophages, and dendritic"/>
 <result pre="SARS-CoV-2 infections is the cytokine release syndrome. SARS-CoV-2 infection of" exact="respiratory" post="epithelial cells activates monocytes, macrophages, and dendritic cells, resulting"/>
 <result pre="infections is the cytokine release syndrome. SARS-CoV-2 infection of respiratory" exact="epithelial" post="cells activates monocytes, macrophages, and dendritic cells, resulting in"/>
 <result pre="cell types, including endothelial cells, resulting in a flood of" exact="systemic" post="cytokine production that contributes to hypotension and acute respiratory"/>
 <result pre="flood of systemic cytokine production that contributes to hypotension and" exact="acute" post="respiratory distress syndrome (ARDS). The key role of IL-6"/>
 <result pre="of systemic cytokine production that contributes to hypotension and acute" exact="respiratory" post="distress syndrome (ARDS). The key role of IL-6 in"/>
 <result pre="cytokine production that contributes to hypotension and acute respiratory distress" exact="syndrome" post="(ARDS). The key role of IL-6 in this cascade"/>
 <result pre="as tocilizumab, sarilumab, and siltuximab for treatment of severe COVID-19" exact="disease" post="(Moore and June, 2020). In addition to increased vascular"/>
 <result pre="COVID-19 disease (Moore and June, 2020). In addition to increased" exact="vascular" post="permeability, the cytokine â€œstormâ€� also leads to high levels"/>
 <result pre="activation of the coagulation cascade on endothelial surfaces of small" exact="blood vessels," post="signaled by very high levels of a fibrin breakdown"/>
 <result pre="of ACE2 by the virus may also induce constriction of" exact="blood vessels." post="A puzzling phenomenon has been seen in COVID-19 pneumonia:"/>
 <result pre="breathlessness. It has been suggested that oxygen uptake in COVID-19" exact="pneumonia" post="is impeded because of clogged and constricted blood vessels"/>
 <result pre="in COVID-19 pneumonia is impeded because of clogged and constricted" exact="blood vessels" post="in the lungs rather than because of congestion from"/>
 <result pre="of edema fluid in the alveoli, as seen in other" exact="viral" post="pneumonias. The benefit of anticoagulants in the treatment of"/>
 <result pre="The benefit of anticoagulants in the treatment of severe COVID-19" exact="disease" post="is therefore of great interest. It is becoming clear"/>
 <result pre="is becoming clear that the pathogenetic cascade triggered by SARS-CoV-2" exact="infection" post="damages many organs in the body, from the kidneys"/>
 <result pre="the brain. Such pathophysiological changes are rarely seen with other" exact="respiratory" post="virus infections. Strategies for Treatment of SARS-CoV-2 Infection There"/>
 <result pre="with other respiratory virus infections. Strategies for Treatment of SARS-CoV-2" exact="Infection" post="There are no licensed drugs that specifically target SARS-CoV-2"/>
 <result pre="use in humans for other indications. Drugs that target specific" exact="viral" post="proteins or critical host cell processes have been selected"/>
 <result pre="study, where the drug was used in patients with severe" exact="disease" post="outside of a clinical trial when no other treatments"/>
 <result pre="useful as adjuncts to antiviral agents (FigureÂ 2). Cytokine release" exact="syndrome" post="and the observation of elevated levels of serum IL-6"/>
 <result pre="as an adjunct to antiviral drugs for treatment of severe" exact="disease" post="(FigureÂ 2). Antibodies can also be administered to prevent"/>
 <result pre="disease (FigureÂ 2). Antibodies can also be administered to prevent" exact="infection" post="in individuals who are known to be at risk"/>
 <result pre="in individuals who are known to be at risk of" exact="infection" post="(FigureÂ 2), referred to as immunoprophylaxis. The optimal timing"/>
 <result pre="therapeutic antibodies should be guided by the phase of the" exact="disease" post="and the kinetics of viral replication and immune response"/>
 <result pre="by the phase of the disease and the kinetics of" exact="viral" post="replication and immune response (FigureÂ 2). Recap A diverse"/>
 <result pre="including coronaviruses, rhinoviruses, RSV, parainfluenza, and influenza viruses, target the" exact="respiratory" post="tract, cause a range of infections from rhinitis to"/>
 <result pre="influenza viruses, target the respiratory tract, cause a range of" exact="infections" post="from rhinitis to pneumonia, and represent a large global"/>
 <result pre="target the respiratory tract, cause a range of infections from" exact="rhinitis" post="to pneumonia, and represent a large global burden of"/>
 <result pre="represent a large global burden of disease. The viruses infect" exact="epithelial" post="cells of the respiratory tract after binding distinct cell"/>
 <result pre="burden of disease. The viruses infect epithelial cells of the" exact="respiratory" post="tract after binding distinct cell surface receptors, and infection"/>
 <result pre="the respiratory tract after binding distinct cell surface receptors, and" exact="infection" post="rapidly triggers innate immune responses. However, viruses employ several"/>
 <result pre="immunity in the host. TÂ cell responses are critical for" exact="viral" post="clearance, and antibody responses directed against respiratory viruses can"/>
 <result pre="are critical for viral clearance, and antibody responses directed against" exact="respiratory" post="viruses can protect against re-infection, although reinfection occurs over"/>
 <result pre="reinfection occurs over the course of a lifetime with many" exact="respiratory" post="viruses. COVID-19 refers to the respiratory illness caused by"/>
 <result pre="a lifetime with many respiratory viruses. COVID-19 refers to the" exact="respiratory" post="illness caused by SARS-CoV-2, a zoonotic coronavirus that emerged"/>
 <result pre="has rapidly spread around the world in a pandemic. COVID-19" exact="pneumonia" post="differs from that caused by other respiratory viruses in"/>
 <result pre="a pandemic. COVID-19 pneumonia differs from that caused by other" exact="respiratory" post="viruses in the severity and duration of inflammation, which"/>
 <result pre="of proinflammatory cytokines, and multiorgan dysfunction, driven by derangements in" exact="pulmonary" post="and clotting physiology. As the pandemic evolves, we are"/>
 <result pre="a Clinically Proven Protease InhibitorCell1812020271280.e832142651 LauerS.A.GrantzK.H.BiQ.JonesF.K.ZhengQ.MeredithH.R.AzmanA.S.ReichN.G.LesslerJ.The Incubation Period of Coronavirus" exact="Disease" post="2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ.Â"/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ.Â Infect. Dis.2112015809025030060"/>
 <result pre="a systematic review and exploratory meta-analysisJ.Â Infect. Dis.2112015809025030060 MatrosovichM.N.MatrosovichT.Y.GrayT.RobertsN.A.KlenkH.D.Human and" exact="avian influenza" post="viruses target different cell types in cultures of human"/>
 <result pre="of human airway epitheliumProc. Natl. Acad. Sci. USA10120044620462415070767 MooreJ.B.JuneC.H.Cytokine release" exact="syndrome" post="in severe COVID-19Science368202047347432303591 PaulesC.SubbaraoK.InfluenzaLancet390201769770828302313 SantA.J.McMichaelA.Revealing the role of CD4(+)"/>
 <result pre="COVID-19Science368202047347432303591 PaulesC.SubbaraoK.InfluenzaLancet390201769770828302313 SantA.J.McMichaelA.Revealing the role of CD4(+) TÂ cells in" exact="viral" post="immunityJ.Â Exp. Med.20920121391139522851641 ThevarajanI.NguyenT.H.O.KoutsakosM.DruceJ.CalyL.van de SandtC.E.JiaX.NicholsonS.CattonM.CowieB.Breadth of concomitant immune"/>
 <result pre="with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialLancet39520201569157832423584 ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.SiH.R.ZhuY.LiB.HuangC.L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
</results>
